Skip to main content
SpringerLink
Log in

Biomarkers for Melanoma

  • Living reference work entry
  • First Online:
Book cover Cutaneous Melanoma

  • 415 Accesses

Abstract

Biomarkers of melanoma may eventually be used in diagnostics, prognostics, as well as prediction of clinical outcome and/or treatment response. These biomarkers may be either clinical characteristics or molecular patterns or profiles, mainly derived from tumor tissue or from the peripheral blood. The molecular biomarkers can be categorized into genetic alterations, epigenetics, proteins, or other types of molecules, which provide a “signature” of risk, prognosis, and/or treatment response. Because of the potential of biomarkers to improve the prognostication and hereby the outcome of patients with melanoma, research is underway to identify and validate melanoma biomarkers from numerous sources, including tumor cells (cultured, freshly biopsied, and paraffin-embedded), draining regional lymph nodes, serum/plasma, tumor environment, and cellular compartments of the peripheral blood. The biomarkers reviewed here comprise tumor tissue-based biomarkers, tumor environment-based biomarkers, soluble biomarkers of the peripheral blood, as well as treatment-associated biomarkers. These biomarkers might not only be useful for diagnostics, prognostication, and prediction of treatment outcomes but in particular for the continuous monitoring of a patient’s course of disease over time.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, Orchard G, Higgins E, Sherwood R, Russell-Jones R (2002) Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 146:832–835

    Article  CAS  PubMed  Google Scholar 

  • Aftab MN, Dinger ME, Perera RJ (2014) The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma. Arch Biochem Biophys 563:60–70

    Article  CAS  PubMed  Google Scholar 

  • Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, Rodriguez-Peralto JL (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles a tissue microarray-based study. Am J Pathol 164:193–203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A (2008) Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14:79–89

    Article  CAS  PubMed  Google Scholar 

  • Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortes-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L (2018) Comprehensive characterization of Cancer driver genes and mutations. Cell 173:371–85.e18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001a) Final version of the American joint committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648

    Article  CAS  PubMed  Google Scholar 

  • Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001b) Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634

    Article  CAS  PubMed  Google Scholar 

  • Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206

    Article  PubMed  PubMed Central  Google Scholar 

  • Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, Queirolo P, Vermi W, Facchetti F, Moretta A, Moretta L, Mingari MC, Vitale M (2009) Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 106:20847–20852

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bennett DC (2008) How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21:27–38

    Article  CAS  PubMed  Google Scholar 

  • Berghuis AM, Koffijberg H, Prakash J, Terstappen LW, IJzerman MJ (2017) Detecting blood-based biomarkers in metastatic breast Cancer: a systematic review of their current status and clinical Utility. Int J Mol Sci 18:363

    Article  PubMed Central  CAS  Google Scholar 

  • Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U (1994) Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54:5695

    CAS  PubMed  Google Scholar 

  • Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R (1989) Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49:5358–5363

    CAS  PubMed  Google Scholar 

  • Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11:130–135

    Article  CAS  PubMed  Google Scholar 

  • Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J (2013) A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol 139:249–258

    Article  CAS  PubMed  Google Scholar 

  • Buchbinder E, Hodi FS (2015) Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 125:3377–3383

    Article  PubMed  PubMed Central  Google Scholar 

  • Calapre L, Warburton L, Millward M, Ziman M, Gray ES (2017) Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett 404:62–69

    Article  CAS  PubMed  Google Scholar 

  • Campisi J, d’Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8:729–740

    Article  CAS  PubMed  Google Scholar 

  • Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E (2013) A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 24:466–480

    Article  CAS  PubMed  Google Scholar 

  • Carlino MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, Nagrial AM, Scolyer RA, Kefford RF, Long GV, Rizos H (2015) Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clin Cancer Res 21:98–105

    Article  CAS  PubMed  Google Scholar 

  • Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA (2017) Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 28:2581–2587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen X, Liang H, Zhang J, Zen K, Zhang CY (2012) Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 22:125–132

    Article  CAS  PubMed  Google Scholar 

  • Clark WH Jr, Elder DE, th Guerry D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893–1904

    Article  PubMed  Google Scholar 

  • Clarke LE, Warf MB, Flake DD 2nd, Hartman AR, Tahan S, Shea CR, Gerami P, Messina J, Florell SR, Wenstrup RJ, Rushton K, Roundy KM, Rock C, Roa B, Kolquist KA, Gutin A, Billings S, Leachman S (2015) Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol 42:244–252

    Article  PubMed  PubMed Central  Google Scholar 

  • Clarke LE, Flake DD 2nd, Busam K, Cockerell C, Helm K, McNiff J, Reed J, Tschen J, Kim J, Barnhill R, Elenitsas R, Prieto VG, Nelson J, Kimbrell H, Kolquist KA, Brown KL, Warf MB, Roa BB, Wenstrup RJ (2017) An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. Cancer 123:617–628

    Article  CAS  PubMed  Google Scholar 

  • Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310

    Article  CAS  PubMed  Google Scholar 

  • Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL (2004) Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17:747–755

    Article  PubMed  Google Scholar 

  • Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P, Fucci M, Pasquini P, Faraggiana T (1996) Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 14:1218–1223

    Article  CAS  PubMed  Google Scholar 

  • Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA (2011) MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat Rev Clin Oncol 8:467–477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cyster JG (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286:2098–2102

    Article  CAS  PubMed  Google Scholar 

  • Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M (2004) BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23:5968–5977

    Article  CAS  PubMed  Google Scholar 

  • De Souza LM, Robertson BM, Robertson GP (2017) Future of circulating tumor cells in the melanoma clinical and research laboratory settings. Cancer Lett 392:60–70

    Article  PubMed  CAS  Google Scholar 

  • Deichmann M, Brenner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H (1999) S100-beta, melanoma-inhibiting activity and lactate dehydrogenase discriminate progressive from non-progressive American joint committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891–6

    Article  CAS  PubMed  Google Scholar 

  • Deichmann M, Kahle B, Moser K, Wacker J, Wust K (2004) Diagnosing melanoma patients entering American joint committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91:699–702

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dror S, Sander L, Schwartz H, Sheinboim D, Barzilai A, Dishon Y, Apcher S, Golan T, Greenberger S, Barshack I, Malcov H, Zilberberg A, Levin L, Nessling M, Friedmann Y, Igras V, Barzilay O, Vaknine H, Brenner R, Zinger A, Schroeder A, Gonen P, Khaled M, Erez N, Hoheisel JD, Levy C (2016) Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol 18:1006–1017

    Article  CAS  PubMed  Google Scholar 

  • Duffy MJ (2013) Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 22:4–11

    Article  PubMed  Google Scholar 

  • Duffy MJ, Crown J (2008) A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54:1770–1779

    Article  CAS  PubMed  Google Scholar 

  • Duffy MJ, O’Donovan N, Crown J (2011) Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 37:151–159

    Article  CAS  PubMed  Google Scholar 

  • Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A (2010) Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Anticancer Res 30:1799–1805

    CAS  PubMed  Google Scholar 

  • Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A (2012) Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer 48:695–702

    Article  CAS  PubMed  Google Scholar 

  • Eisenstein A, Gonzalez EC, Raghunathan R, Xu X, Wu M, McLean EO, McGee J, Ryu B, Alani RM (2018) Emerging biomarkers in cutaneous melanoma. Mol Diagn Ther 22:203–218

    Article  CAS  PubMed  Google Scholar 

  • English K (2013) Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 91:19–26

    Article  CAS  PubMed  Google Scholar 

  • Farmer ER, Gonin R, Hanna MP (1996) Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 27:528–531

    Article  CAS  PubMed  Google Scholar 

  • Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, Mancini R, Ciliberto G (2017) MicroRNAs in melanoma development and resistance to target therapy. Oncotarget 8:22262–22278

    Article  PubMed  PubMed Central  Google Scholar 

  • Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S (2009) Serum amyloid a as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 23:2199–2208

    Article  CAS  Google Scholar 

  • Friedman EB, Shang S, de Miera EV, Fog JU, Teilum MW, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando E, Baker A, Shao Y, Osman I (2012) Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 10:155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fu W, Li J, Zhang W, Li P (2017) High expression of CD47 predicts adverse prognosis in Chinese patients and suppresses immune response in melanoma. Biomed Pharmacother 93:1190–1196

    Article  CAS  PubMed  Google Scholar 

  • Fuentes-Arderiu X (2013) What is a biomarker? It’s time for a renewed definition. Clin Chem Lab Med 51:1689–1690

    Article  CAS  PubMed  Google Scholar 

  • Fuzery AK, Levin J, Chan MM, Chan DW (2013) Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 10:13

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Gaiser T, Kutzner H, Palmedo G, Siegelin MD, Wiesner T, Bruckner T, Hartschuh W, Enk AH, Becker MR (2010) Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. Mod Pathol 23:413–419

    Article  CAS  PubMed  Google Scholar 

  • Garrido-Ruiz MC, Requena L, Ortiz P, Perez-Gomez B, Alonso SR, Peralto JL (2010) The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study. Mod Pathol 23:1215–1224

    Article  CAS  PubMed  Google Scholar 

  • George E, Polissar NL, Wick M (2010) Immunohistochemical evaluation of p16INK4A, E-cadherin, and cyclin D1 expression in melanoma and Spitz tumors. Am J Clin Pathol 133:370–379

    Article  PubMed  Google Scholar 

  • Gerami P, Jewell SS, Morrison LE, Blondin B, Schulz J, Ruffalo T, th Matushek P, Legator M, Jacobson K, Dalton SR, Charzan S, Kolaitis NA, Guitart J, Lertsbarapa T, Boone S, LeBoit PE, Bastian BC (2009) Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 33:1146–1156

    Article  PubMed  Google Scholar 

  • Gerami P, Li G, Pouryazdanparast P, Blondin B, Beilfuss B, Slenk C, Du J, Guitart J, Jewell S, Pestova K (2012) A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol 36:808–817

    Article  PubMed  Google Scholar 

  • Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, Lyle S, Jackson GL, Greisinger AJ, Johnson CE, Oelschlager KM, Stone JF, Maetzold DJ, Ferris LK, Wayne JD, Cooper C, Obregon R, Delman KA, Lawson D (2015a) Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72:780–5.e3

    Article  CAS  PubMed  Google Scholar 

  • Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, Gonzalez R, Lyle S, Johnson CE, Oelschlager KM, Jackson GL, Greisinger AJ, Maetzold D, Delman KA, Lawson DH, Stone JF (2015b) Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21:175–183

    Article  CAS  PubMed  Google Scholar 

  • Gerami P, Yao Z, Polsky D, Jansen B, Busam K, Ho J, Martini M, Ferris LK (2017) Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol 76:114–20.e2

    Article  CAS  PubMed  Google Scholar 

  • Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF (2017) Melanoma staging: evidence-based changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472–492

    Article  PubMed  PubMed Central  Google Scholar 

  • Goossens N, Nakagawa S, Sun X, Hoshida Y (2015) Cancer biomarker discovery and validation. Transl Cancer Res 4:256–269

    CAS  PubMed  Google Scholar 

  • Gould Rothberg BE, Rimm DL (2010) Biomarkers: the useful and the not so useful–an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 130:1971–1987

    Article  CAS  PubMed  Google Scholar 

  • Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL (2009a) Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 27:5772–5780

    Article  PubMed  PubMed Central  Google Scholar 

  • Gould Rothberg BE, Bracken MB, Rimm DL (2009b) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101:452–474

    Article  PubMed  CAS  Google Scholar 

  • Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M (2015) Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6:42008–42018

    PubMed  PubMed Central  Google Scholar 

  • Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170–177

    Article  CAS  PubMed  Google Scholar 

  • Group, Biomarkers Definitions Working (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95

    Article  Google Scholar 

  • Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D (1995) Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A:924–928

    Article  CAS  PubMed  Google Scholar 

  • Hauschild A, Engel G, Brenner W, Glaeser R, Moenig H, Henze E, Christophers E (1999a) Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140:1065–1071

    Article  CAS  PubMed  Google Scholar 

  • Hauschild A, Engel G, Brenner W, Glaeser R, Monig H, Henze E, Christophers E (1999b) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–344

    Article  CAS  PubMed  Google Scholar 

  • Holtzhausen A, Zhao F, Evans KS, Tsutsui M, Orabona C, Tyler DS, Hanks BA (2015) Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and Immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res 3:1082–1095

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014–4022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang SK, Hoon DS (2016) Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol 10:450–463

    Article  PubMed  CAS  Google Scholar 

  • Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D’Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60–65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (2017) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 168:542

    Article  CAS  PubMed  Google Scholar 

  • Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD (2006) CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1′. J Biol Chem 281:26069–26080

    Article  CAS  PubMed  Google Scholar 

  • Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13:e32–e42

    Article  CAS  PubMed  Google Scholar 

  • Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271–285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M, Ihn H (2011) The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 61:187–193

    Article  CAS  PubMed  Google Scholar 

  • Kashani-Sabet M, Venna S, Rangel J et al (2009) A multi-marker prognostic assay for melanoma. Clin Cancer Res 15:6987–6992

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kashani-Sabet M, Nosrati M, Miller JR 3rd, Sagebiel RW, Leong SPL, Lesniak A, Tong S, Lee SJ, Kirkwood JM (2017) Prospective validation of molecular prognostic markers in cutaneous melanoma: a correlative analysis of E1690. Clin Cancer Res 23:6888–6892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kaur S, Roberts DD (2016) Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling. Int J Biochem Cell Biol 81:184–194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kawasaki K, Kawakami T, Watabe H, Itoh F, Mizoguchi M, Soma Y (2007) Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma. Br J Dermatol 156:613–619

    Article  CAS  PubMed  Google Scholar 

  • Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C (2013) Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol 133:1582–1590

    Article  CAS  PubMed  Google Scholar 

  • Khoja L, Shenjere P, Hodgson C, Hodgetts J, Clack G, Hughes A, Lorigan P, Dive C (2014) Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res 24:40–46

    Article  CAS  PubMed  Google Scholar 

  • Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A (2015) Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Ann Oncol 26:33–39

    Article  CAS  PubMed  Google Scholar 

  • Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA (2014) A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov 4:816–827

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Koyanagi K, O’Day SJ, Gonzalez R et al (2005) Serial monitoring of circulating melanoma cells during neoadjuvant bio-chemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 23:8057

    Article  PubMed  Google Scholar 

  • Krähn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU (2001) S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 21:1311–1316

    PubMed  Google Scholar 

  • Krogh M, Christensen I, Bouwhuis M, Johansen JS, Norgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L (2016) Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res 26:367–376

    Article  CAS  PubMed  Google Scholar 

  • Kulasingam V, Diamandis EP (2008) Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 5:588–599

    Article  CAS  PubMed  Google Scholar 

  • Lai CY, Schwartz BE, Hsu MY (2012) CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res 72:5111–5118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee JH, Chen Y, Chan JL, Qian YW, Goydos JS (2011) Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction. Cancer Immunol Immunother 60:685–692

    Article  CAS  PubMed  Google Scholar 

  • Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H (2017) Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 28:1130–1136

    Article  CAS  PubMed  Google Scholar 

  • Li JP, Lu L, Wang LJ, Zhang FR, Shen WF (2011) Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure. Clin Biochem 44:984–988

    Article  CAS  PubMed  Google Scholar 

  • Li FZ, Dhillon AS, Anderson RL, McArthur G, Ferrao PT (2015) Phenotype switching in melanoma: implications for progression and therapy. Front Oncol 5:31

    Article  PubMed  PubMed Central  Google Scholar 

  • Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:1135–1146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H (2018) Liquid biomarkers in melanoma: detection and discovery. Mol Cancer 17:8

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H (2018) An integrated TCGA pan-Cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173:400–16.e11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA (2016) Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17:1743–1754

    Article  CAS  PubMed  Google Scholar 

  • Mandala M, Massi D (2014) Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch 464:265–281

    Article  CAS  PubMed  Google Scholar 

  • Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of eastern cooperative oncology group trials. J Clin Oncol 18:3782–3793

    Article  CAS  PubMed  Google Scholar 

  • Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B (2016) Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with Ipilimumab. Clin Cancer Res 22:2908–2918

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, Mandala M (2017) Baseline beta-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. Eur J Cancer 78:70–81

    Article  CAS  PubMed  Google Scholar 

  • Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (2017) The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev 276:145–164

    Article  CAS  PubMed  Google Scholar 

  • McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, Meniawy TM, Pritchard AL, Hayward NK, Amanuel B, Millward M, Ziman M, Gray ES (2017) Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget 8:78890–78900

    Article  PubMed  PubMed Central  Google Scholar 

  • McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA (2018) Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 19:310–322

    Article  PubMed  PubMed Central  Google Scholar 

  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005a) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067–9072

    Article  PubMed  Google Scholar 

  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005b) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51–65

    Article  CAS  PubMed  Google Scholar 

  • Minca EC, Al-Rohil RN, Wang M, Harms PW, Ko JS, Collie AM, Kovalyshyn I, Prieto VG, Tetzlaff MT, Billings SD, Andea AA (2016) Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. Mod Pathol 29:832–843

    Article  CAS  PubMed  Google Scholar 

  • Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, Pilati P, Nitti D, Lise M, Rossi CR (2004) Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 111:741–745

    Article  CAS  PubMed  Google Scholar 

  • Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR (2006) The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 12:4605–4613

    Article  CAS  PubMed  Google Scholar 

  • Mocellin S, Zavagno G, Nitti D (2008) The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 123:2370–2376

    Article  CAS  PubMed  Google Scholar 

  • Mordente A, Meucci E, Martorana GE, Silvestrini A (2015) Cancer biomarkers discovery and validation: state of the art, problems and future perspectives. Adv Exp Med Biol 867:9–26

    Article  CAS  PubMed  Google Scholar 

  • Mori T, O’Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ, Vu VD, Nguyen SL, Hoon DS (2005) Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 23:9351–9358

    Article  CAS  PubMed  Google Scholar 

  • Mori T, Martinez SR, O’Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang HJ, Hoon DS (2006) Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 66:6692–6698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS (2014) Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun 5:5712

    Article  PubMed  CAS  Google Scholar 

  • Neagu M, Constantin C, Longo C (2015) Chemokines in the melanoma metastasis biomarkers portrait. J Immunoassay Immunochem 36:559–566

    Article  CAS  PubMed  Google Scholar 

  • Network, The Cancer Genome Atlas (2015) Genomic classification of cutaneous melanoma. Cell 161:1681–1696

    Article  CAS  Google Scholar 

  • Newman AM, Bratman SV, J. To, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, Diehn M (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20:548–554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, Gogas H, Stratigos AJ, Katsambas AD, Koutsilieris M (2011) Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev 37:284–290

    Article  CAS  PubMed  Google Scholar 

  • Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S (2009) Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15:5208–5215

    Article  CAS  PubMed  Google Scholar 

  • Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054–1061

    Article  CAS  PubMed  Google Scholar 

  • Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, Pahlman S (1987) S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18:911–918

    Article  CAS  PubMed  Google Scholar 

  • Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72:1407–1415

    Article  CAS  PubMed  Google Scholar 

  • Poste G (2011) Bring on the biomarkers. Nature 469:156–157

    Article  CAS  PubMed  Google Scholar 

  • Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H (2002) Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 100:580–585

    Article  CAS  PubMed  Google Scholar 

  • Rothhammer T, Bosserhoff AK (2007) Epigenetic events in malignant melanoma. Pigment Cell Res 20:92–111

    Article  CAS  PubMed  Google Scholar 

  • Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N (2018) Oncogenic signaling pathways in the Cancer genome atlas. Cell 173:321–37.e10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sanmamed MF, Carranza-Rua O, Alfaro C, Onate C, Martin-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Munoz-Calleja C, Rodriguez-Ruiz M, Sangro B, Lopez-Picazo JM, Rizzo M, Mazzolini G, Pascual JI, Andueza MP, Perez-Gracia JL, Melero I (2014) Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20:5697–5707

    Article  CAS  PubMed  Google Scholar 

  • Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020–2027

    Article  PubMed  Google Scholar 

  • Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS (2013) Chemokines in tumor progression and metastasis. Oncotarget 4:2171–2185

    Article  PubMed  PubMed Central  Google Scholar 

  • Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH (2008) Identification of cells initiating human melanomas. Nature 451:345–349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schatton T, Schutte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH (2010) Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 70:697–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A (2010) Aberrant DNA methylation in malignant melanoma. Melanoma Res 20:253–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H (2006) Serum YKL-40 predicts relapse-free and overall survival in patients with American joint committee on Cancer stage I and II melanoma. J Clin Oncol 24:798–804

    Article  CAS  PubMed  Google Scholar 

  • Schultz ES, Diepgen TL, Von Den Driesch P (1998) Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 138:426–430

    Article  CAS  PubMed  Google Scholar 

  • Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437

    Article  CAS  PubMed  Google Scholar 

  • Scolyer RA, Shaw HM, Thompson JF, Li LX, Colman MH, Lo SK, McCarthy SW, Palmer AA, Nicoll KD, Dutta B, Slobedman E, Watson GF, Stretch JR (2003) Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 27:1571–1576

    Article  PubMed  Google Scholar 

  • Shoo BA, Sagebiel RW, Kashani-Sabet M (2010) Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol 62:751–756

    Article  PubMed  Google Scholar 

  • Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, Jacob S, Gal M, Michal L (2012) Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 2012:290536

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, Pauwels P (2017) A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn 19:162–168

    Article  CAS  PubMed  Google Scholar 

  • Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M, van Gele M, Thielemans K, Neyns B, Roche N, Verbeke N, Deron P, Speeckaert M, Brochez L (2012) Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 48:2004–2011

    Article  CAS  PubMed  Google Scholar 

  • Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523:231–235

    Article  CAS  PubMed  Google Scholar 

  • Stagni C, Zamuner C, Elefanti L, Zanin T, Bianco PD, Sommariva A, Fabozzi A, Pigozzo J, Mocellin S, Montesco MC, Chiarion-Sileni V, De Nicolo A, Menin C (2018) BRAF gene copy number and mutant allele frequency correlate with time to progression in metastatic melanoma patients treated with MAPK inhibitors. Mol Cancer Ther 17:1332–1340

    Article  CAS  PubMed  Google Scholar 

  • Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK (2015) The prognostic and predictive value of melanoma-related MicroRNAs using tissue and serum: a MicroRNA expression analysis. EBioMedicine 2:671–680

    Article  PubMed  PubMed Central  Google Scholar 

  • Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15:1801–1807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ugurel S (2005) Serological markers of melanoma. Hautarzt 2:173

    Article  Google Scholar 

  • Ugurel S, Rappl G, Tilgen W, Reinhold U (2001a) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577–583

    Article  CAS  PubMed  Google Scholar 

  • Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U (2001b) Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92:369–376

    Article  CAS  PubMed  Google Scholar 

  • Vaquero J, Jordano Q, Lee WM, Blei AT (2003) Serum protein S-100b in acute liver failure: results of the US acute liver failure study group. Liver Transpl 9:887–888

    Article  PubMed  Google Scholar 

  • Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T (2012) NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer 106:1446–1452

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Warton K, Samimi G (2015) Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci 2:13

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kahler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD (2016) Baseline biomarkers for outcome of melanoma patients treated with Pembrolizumab. Clin Cancer Res 22:5487–5496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PO, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662–6667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wilson BJ, Saab KR, Ma J, Schatton T, Putz P, Zhan Q, Murphy GF, Gasser M, Waaga-Gasser AM, Frank NY, Frank MH (2014) ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res 74:4196–4207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van Den Oord JJ, Spatz A (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472–482

    Article  CAS  PubMed  Google Scholar 

  • Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, Wong P, Wu X, Naidoo J, Page DB, Wolchok JD, Hodi FS (2014) Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2:127–132

    Article  CAS  PubMed  Google Scholar 

  • Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisinger A, Estrada SI, Pariser DM, Cranmer LD, Messina JL, Vetto JT, Wayne JD, Delman KA, Lawson DH, Gerami P (2018) Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 18:130

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ziani L, Safta-Saadoun TB, Gourbeix J, Cavalcanti A, Robert C, Favre G, Chouaib S, Thiery J (2017) Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget 8:19780–19794

    Article  PubMed  PubMed Central  Google Scholar 

  • Zuo Q, Liu J, Huang L, Qin Y, Hawley T, Seo C, Merlino G, Yu Y (2018) AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene 37:3275–3289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital Essen, Essen, Germany

    Dirk Schadendorf & Selma Ugurel

  2. German Cancer Consortium, Heidelberg, Germany

    Dirk Schadendorf

  3. Cancer Center, Massachusetts General Hospital, Boston, MA, USA

    Keith T. Flaherty

  4. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Lyn M. Duncan

  5. Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA, USA

    Mohammed Kashani-Sabet

Authors
  1. Dirk Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith T. Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lyn M. Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammed Kashani-Sabet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Selma Ugurel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Schadendorf .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, University of Texas Southwestern, Dallas, TX, USA

    Charles Balch

  2. Division of Surgery, UT MD Anderson Cancer Center, Houston, TX, USA

    Jeffrey Gershenwald

  3. Melanoma Institute of Australia, Wollstonecraft, Australia

    John Thompson

  4. Georgetown Medical Center, Washington, DC, USA

    Michael Atkins

  5. Melanoma and Skin Cancer Program, University of Pittsburgh, Pittsburgh, PA, USA

    John Kirkwood

  6. University of Sydney, Sydney, NSW, Australia

    Richard Kefford

  7. Department of Dermatology, Harvard Medical Center, Boston, MA, USA

    Arthur Sober

  8. Department of Dermatology, Memorial Sloan Kettering, New York, NY, USA

    Allan Halpern

  9. Department of Dermatology, University Hospital, Tübingen, Tübingen, Germany

    Claus Garbe

  10. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown NSW, Australia

    Richard Scolyer

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Schadendorf, D., Flaherty, K.T., Duncan, L.M., Kashani-Sabet, M., Ugurel, S. (2019). Biomarkers for Melanoma. In: Balch, C., et al. Cutaneous Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-46029-1_45-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46029-1_45-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46029-1

  • Online ISBN: 978-3-319-46029-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation